Evidence map›Paper›PMID 39788500›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2024

Efficacy of

Peng Fang, Yin Gao, Hongya Xin, Linxin Liu, Yi Liu, Yajing Xu, Yan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peng FangDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008. pengfgy@csu.edu.cn.
Yin Gao
Hongya XinDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Linxin LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Yi LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Yajing XuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Yan ChenDepartment of Hematology, Xiangya Hospital, Central South University, Changsha 410008. yanchen2018@csu.edu.cn.

Funding

the China Anti-Cancer Association-Hengrui TPO Receptor Agonist Research Fund CORP-253
6 · The paper itself

Abstract

objectivesMonitoring minimal residual disease (MRD) and timely intervention are effective strategies for preventing relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult acute myeloid leukemia (AML). The

methodsData of adult AML patients with intermediate or high-risk cytogenetics who underwent allo-HSCT between January 2014 and June 2020 at the Department of Hematology, Xiangya Hospital, Central South University, were retrospectively collected. All patients had

resultsA total of 165 AML patients were included, of whom 86 had

conclusionssequential monitoring of

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteNeoplasm, ResidualWT1 ProteinsAdultDisease-Free SurvivalFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesSurvival RateTransplantation, HomologousWT1 protein, humanWT1 Proteinsacute myeloid leukemiahematopoietic stem cell transplantationminimal residual diseasepreemptive therapyWT1 gene

Identifiers

PMID39788500
PMCPMC11495973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.